Macrogenics Inc (MGNX): R&D Expense
$147.17M
Year ended 2025-12-31
$140.44M
Trailing 12 months to 2026-06-30
-10.8%
3-year compound annual growth
-5.3%
5-year compound annual growth
+4.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $147.17M | -16.9% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $177.19M | +6.4% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $166.58M | -19.5% | 2026-03-09, From 2023-01-01 |
| 2022-12-31 | $207.03M | -3.5% | 2025-03-20, From 2022-01-01 |
| 2021-12-31 | $214.58M | +11.1% | 2024-03-07, From 2021-01-01 |
| 2020-12-31 | $193.20M | -1.1% | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $195.31M | +2.3% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $190.83M | +29.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $147.23M | +20.6% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $122.09M | +24.2% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $98.27M | +40.0% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $70.19M | +50.7% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $46.58M | +2.5% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $45.43M | +10.6% | 2015-03-03, From 2012-01-01 |
| 2011-12-31 | $41.09M | n/a | 2014-03-20, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Macrogenics Inc (MGNX) | 2025-12-31 | $147.17M | -16.9% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $5.74M | -27.9% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $125.62M | -12.3% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $12.43M | -25.5% |
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $32.78M | -3.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
Compare MGNX, ELTP, KPTI, HRTX side by side · Screen every company in Pharmaceutical Preparations ↗